Screening Women for Chlamydia trachomatis in Family Planning Clinics: The Cost‐Effectiveness of DNA Amplification Assays

Background: Highly sensitive and specific DNA amplification assays are available for use on cervical and urine specimens. These new tests have the potential to identify more chlamydial infections than the commonly used enzyme immunoassay and DNA probe tests, yet they are more expensive. This study sought to assess the cost effectiveness of cell culture, enzyme immunoassay (EIA), DNA probe (Pace 2), polymerase chain reaction (PCR) of cervical and urine specimens, and ligase chain reaction (LCR) of cervical and urine specimens as screening tools for Chlamydia trachomatis in asymptomatic women younger than 30 years of age attending family planning clinics. Study Design: Program costs; medical cost savings of prevented sequelae in women, male sex partners, and infant; and number of prevented cases of pelvic inflammatory disease (PID), neonatal infections, and male sex partner urethritis and epididymitis were modeled in a decision analysis conducted from a health care system perspective. Results are expressed for a cohort of 18,000 women. Results: If no screening forC. trachomatis were conducted in Maryland, 497 cases of PID would develop, costing $2.2 million in future medical costs. Use of EIA to detect chlamydial infection would prevent 240 cases of PID and save $887,000 over no screening. Alternatively, use of DNA amplification assays on urine specimens would prevent up to an additional 66 cases and save $287,100 over EIA. Use of LCR on cervical specimens would prevent at least 13 additional cases of PID over the urine‐based assays, but would cost $3,005 for each additional case prevented. In women receiving routine pelvic examinations, LCR of cervical specimens would prevent the most disease and provide the highest cost savings. In women not receiving routine pelvic examinations, use of LCR on cervical specimens would prevent the most disease but would cost approximately $28,000 per additional case of PID prevented over DNA amplification of urine. Conclusions: Compared with EIA screening, the strategy with the lowest program costs, a screening strategy that combines use of DNA amplification on cervical specimens in women receiving pelvic examinations, and DNA amplification of urine in women with no medical indications necessitating a pelvic examination, prevents the most cases of PID and provides the highest cost savings. With enhanced sensitivity over the other diagnostic assays and with the use of noninvasive specimen collection, DNA amplification assays should be implemented as cost‐effective components of a screening program for C. trachomatis.

[1]  Helen H. Lee,et al.  Noninvasive tests for diagnosis of Chlamydia trachomatis infection: application of ligase chain reaction to first-catch urine specimens of women. , 1995, The Journal of infectious diseases.

[2]  M. Anderka,et al.  Prospective study of maternal and infantile infection with Chlamydia trachomatis. , 1979, Pediatrics.

[3]  K. Holmes,et al.  Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. , 1984, The New England journal of medicine.

[4]  G. V. van Doornum,et al.  Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by ligase chain reaction-based assays with clinical specimens from various sites: implications for diagnostic testing and screening , 1996, Journal of clinical microbiology.

[5]  D. Low,et al.  Use of the polymerase chain reaction for the detection of Chlamydia trachomatis from endocervical and urine specimens in an asymptomatic low-prevalence population of women. , 1994, Diagnostic microbiology and infectious disease.

[6]  M. Borrego,et al.  Comparison of the Amplicor Chlamydia trachomatis test and cell culture for the detection of urogenital chlamydial infections. , 1995, Genitourinary medicine.

[7]  A. Miettinen,et al.  Detection of Chlamydia trachomatis infections in women by Amplicor PCR: comparison of diagnostic performance with urine and cervical specimens , 1996, Journal of clinical microbiology.

[8]  P. Morel,et al.  An Evaluation of the Polymerase Chain Reaction Amplicor Chlamydia trachomatis in Male Urine and Female Urogenital Specimens , 1994, Sexually transmitted diseases.

[9]  J. Zenilman,et al.  Diagnosis by AMPLICOR PCR of Chlamydia trachomatis infection in urine samples from women and men attending sexually transmitted disease clinics , 1996, Journal of clinical microbiology.

[10]  J. Covino,et al.  Comparison of the Syva MicroTrak enzyme immunoassay and Gen-Probe PACE 2 with cell culture for diagnosis of cervical Chlamydia trachomatis infection in a high-prevalence female population , 1993, Journal of clinical microbiology.

[11]  W. Stamm,et al.  Diagnosis of Chlamydia trachomatis endocervical infections by a commercial polymerase chain reaction assay , 1993, Journal of clinical microbiology.

[12]  J. Burczak,et al.  Detection of Chlamydia trachomatis in urine specimens from women by ligase chain reaction , 1995, Journal of clinical microbiology.

[13]  Helen H. Lee,et al.  Diagnosis of Chlamydia trachomatis infections in men and women by testing first-void urine by ligase chain reaction , 1994, Journal of clinical microbiology.

[14]  J. Schwartz,et al.  Doxycycline Compared with Azithromycin for Treating Women with Genital Chlamydia trachomatis Infections: An Incremental Cost-Effectiveness Analysis , 1996, Annals of Internal Medicine.

[15]  M. Shepard,et al.  Recovery of Chlamydia trachomatis from the endometrium of women at risk for chlamydial infection. , 1986, American journal of obstetrics and gynecology.

[16]  T. Quinn,et al.  Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. , 1996, JAMA.

[17]  L. Pickard,et al.  Role of confirmatory PCRs in determining performance of Chlamydia Amplicor PCR with endocervical specimens from women with a low prevalence of infection , 1994, Journal of clinical microbiology.

[18]  B. Dwyer,et al.  Comparative evaluation of detection assays for Chlamydia trachomatis , 1991, Journal of clinical microbiology.

[19]  H. Handsfield,et al.  Performance and Cost‐Effectiveness of Selective Screening Criteria for Chlamydia trachomatis Infection in Women: Implications for a National Chlamydia Control Strategy , 1997, Sexually transmitted diseases.

[20]  T. Quinn,et al.  Evaluation of Syva enzyme immunoassay for detection of Chlamydia trachomatis in genital specimens , 1990, Journal of clinical microbiology.

[21]  S. Thompson,et al.  Pelvic Inflammatory Disease and Fertility: A Cohort Study of 1,844 Women with Laparoscopically Verified Disease and 657 Control Women with Normal Laparoscopic Results , 1992, Sexually transmitted diseases.

[22]  W. Stamm,et al.  Asymptomatic Chlamydia trachomatis urethritis in men. , 1986, Sexually transmitted diseases.

[23]  Schachter,et al.  Ligase chain reaction to detect Chlamydia trachomatis infection of the cervix , 1994, Journal of clinical microbiology.

[24]  Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. , 1996 .

[25]  P. Katz,et al.  Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000. , 1991 .

[26]  Helen H. Lee,et al.  Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urine , 1995, The Lancet.

[27]  J. Kellogg,et al.  Nonculture tests for genital tract chlamydial infection. What does the package insert mean, and will it mean the same thing tomorrow? , 1992, Sexually transmitted diseases.

[28]  R. Limberger,et al.  Evaluation of culture and the Gen-Probe PACE 2 assay for detection of Neisseria gonorrhoeae and Chlamydia trachomatis in endocervical specimens transported to a state health laboratory , 1992, Journal of clinical microbiology.

[29]  A. Haddix,et al.  The Cost Effectiveness of Azithromycin for Chlamydia trachomatis Infections in Women , 1995, Sexually transmitted diseases.

[30]  P. Larsson,et al.  Expanded gold standard in the diagnosis of Chlamydia trachomatis in a low prevalence population: diagnostic efficacy of tissue culture, direct immunofluorescence, enzyme immunoassay, PCR and serology. , 1994, Genitourinary medicine.

[31]  C. Henquet,et al.  Detection of Chlamydia trachomatis infection in urine samples from men and women by ligase chain reaction , 1995, Journal of clinical microbiology.

[32]  E. Peterson,et al.  Comparison of the Clearview Chlamydia, the PACE 2 assay, and culture for detection of Chlamydia trachomatis from cervical specimens in a low-prevalence population , 1993, Journal of clinical microbiology.

[33]  E. Rees The treatment of pelvic inflammatory disease. , 1980, American journal of obstetrics and gynecology.

[34]  A. Washington,et al.  Chlamydia trachomatis infections in the United States. What are they costing us? , 1987, JAMA.

[35]  C. A. Bass,et al.  Clinical evaluation of a new polymerase chain reaction assay for detection of Chlamydia trachomatis in endocervical specimens , 1993, Journal of clinical microbiology.

[36]  Tammy O. Tengs,et al.  Five-hundred life-saving interventions and their cost-effectiveness. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[37]  M. Frederiksen,et al.  Single-dose methotrexate for the treatment of ectopic pregnancy: Northwestern Memorial Hospital three-year experience. , 1996, American journal of obstetrics and gynecology.

[38]  T. Quinn,et al.  Use of cell culture and a rapid diagnostic assay for Chlamydia trachomatis screening. , 1994, JAMA.

[39]  C. Begley,et al.  The Incremental Cost of Screening, Diagnosis, and Treatment of Gonorrhea and Chlamydia in a Family Planning Clinic , 1989, Sexually transmitted diseases.

[40]  R. Sweet,et al.  Prospective study of perinatal transmission of Chlamydia trachomatis. , 1986, JAMA.